COVID-19 mRNA Vaccine-induced Pneumonitis

Intern Med. 2022 Jan 1;61(1):81-86. doi: 10.2169/internalmedicine.8310-21. Epub 2021 Oct 26.

Abstract

A 65-year-old man experienced cough and shortness of breath 3 days after receiving the first dose of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine. Chest X-ray revealed bilateral infiltrates, and the desaturation deteriorated rapidly. The symptoms and radiographic abnormalities rapidly improved after the initiation of corticosteroid therapy. Intradermal testing of the Pfizer-BioNTech COVID-19 vaccine showed a delayed positive reaction. Based on these findings, the patient was diagnosed with COVID-19 vaccine-induced pneumonitis. The timing of the onset of pneumonitis after vaccination and the results of intradermal testing suggest that Type IV hypersensitivity against COVID-19 vaccine may have been responsible for this clinical condition.

Keywords: COVID-19; intradermal testing; mRNA vaccine; vaccine-induced pneumonitis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • BNT162 Vaccine
  • COVID-19 Vaccines*
  • COVID-19*
  • Humans
  • Male
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Vaccines, Synthetic
  • mRNA Vaccines
  • BNT162 Vaccine